Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis by Velez, Maria V.Luna et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/203709
 
 
 
Please be advised that this information was generated on 2020-09-10 and may be subject to
change.
Oncogene (2019) 38:3696–3709
https://doi.org/10.1038/s41388-019-0696-7
ARTICLE
Suppression of prostate tumor cell survival by antisense
oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis
Maria V. Luna Velez1 ● Gerald W. Verhaegh1 ● Frank Smit2 ● J. P. Michiel Sedelaar1 ● Jack A. Schalken1
Received: 5 July 2018 / Revised: 12 December 2018 / Accepted: 4 January 2019 / Published online: 21 January 2019
© The Author(s) 2019. This article is published with open access
Abstract
One of the mechanisms by which advanced prostate cancer develops resistance to androgen deprivation therapy is the
elevated expression of C-terminally truncated androgen receptor (AR) variants. These variants, such as AR-V7, originate
from aberrant splicing of the AR pre-mRNA and the inclusion of a cryptic exon containing a premature stop codon in the
mRNA. The resulting loss of the ligand-binding domain allows AR-V7 to act as a constitutively active transcription factor.
Here, we designed two antisense oligonucleotides (AONs) directed against cryptic splicing signals within the AR pre-
mRNA. These two AONs, AON-ISE and AON-ESE, demonstrated high efficiency in silencing AR-V7 splicing without
affecting full-length AR expression. The subsequent downregulation of AR-V7-target gene UBE2C was accompanied by
inhibition of androgen-independent cell proliferation and induction of apoptosis in castration-resistant prostate cancer
(CRPC)-derived cell line models 22Rv1, DuCaP, and VCaP. Our results show that splicing-directed AONs can efficiently
prevent expression of AR-V7, providing an attractive new therapeutic option for the treatment of CRPC.
Introduction
Despite the clinical remission achieved by androgen
deprivation therapy, advanced prostate cancer eventually
progresses into recurrent or castration-resistant prostate
cancer (CRPC) [1]. CRPC is a lethal disease with no
curative treatment available and with a median survival of
1–2 years [2, 3]. One mechanism of CRPC progression is
the elevated expression of androgen receptor splice variants
(AR-Vs). Although many AR-Vs have been described, AR-
splice variant 7 (AR-V7) is the most commonly and abun-
dantly expressed variant in human CRPC tissues [4, 5]. AR-
V7 expression is correlated with a bad prognosis and a high
probability of disease recurrence [4–7]. AR-V7 lacks the
ligand-binding domain (LBD) and is constitutively active,
i.e., it can promote androgen-independent cell proliferation
in vitro [8] and tumor growth in vivo under castrate
androgen levels [5]. Due to the lack of the LBD, its activity
is insensitive to the AR antagonists, bicalutamide and
enzalutamide, agents currently used as prostate cancer
therapeutics [8–11].
AR-V7 originates from alternative splicing of the AR pre-
mRNA. A typical splicing process requires the coordinated
action of splicing factors and cis-acting regulatory elements.
Intron 3 of the AR contains two splicing signals known as
intronic and exonic splicing enhancers (ISE and ESE,
respectively). Recognition of these cis elements by the
splicing machinery results in the inclusion of a cryptic exon
3 (CE3) into the mRNA. This cryptic exon includes a
premature stop codon leading to the synthesis of AR-V7
[12]. Blocking these signals could prevent splicing and
inclusion of CE3, leading to the expression of a full-length
AR mRNA (AR-FL) and this potentially could be used as a
mean to re-sensitize tumor cells to current androgen depri-
vation therapy.
Antisense oligonucleotides (AONs) are single stranded,
short molecules that can block (aberrant) splicing events by
base-pairing with cryptic splice sites in the pre-mRNA in
the nucleus [13, 14]. In the present study, we describe the
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use of AONs to prevent AR-V7 mRNA synthesis in CRPC-
derived cell line models 22Rv1, DuCaP, and VCaP. We
show that splicing-directed AONs specifically and effi-
ciently knockdown expression of this variant. The AON-
mediated suppression of AR-V7 has an inhibitory effect of
androgen-independent cell proliferation. Our results provide
the first proof of principle for the use of splice-switching
AONs in CRPC and highlights their potential as therapeutic
agents.
Results
Identification of cis-acting splicing enhancer
elements in AR CE3
For the identification of cis-acting splicing enhancer ele-
ments within the so-called CE3 sequence [4, 5] and its
flanking regions, we used the publically available
computer-based algorithms ACESCAN2 [15] and ESE-
Finder [16, 17] to predict potential ISE and ESE sites,
respectively. Four ISE sites were identified in the flanking
region upstream of CE3 and its cryptic splice acceptor (SA)
site. This SA site was detected by screening the same
sequence with the NetGene2 server [18]. Two ESE sites
were found close to the 3′ end of the CE3 sequence. One
AON, named AON-ISE, was designed such that it
encompasses all four ISE motifs, as well as the detected
cryptic SA site (Fig. 1). A second AON, designated AON-
ESE, was designed encompassing both ESE motifs in CE3
(Fig. 1). Both AONs were generated with a phosphor-
othioate backbone [19] and 2′-O-methyl group modifica-
tions at the sugar chain [20, 21] to make them resistant to
RNAse activity.
AON-mediated suppression of AR-V7 mRNA
synthesis and expression
Next, we evaluated the splicing inhibitory potential of the
AONs in vitro. An AR minigene was created with CE3 and
its flanking regions inserted in between exon 3 and exon 4
and flanking regions of the human AR gene (Fig. 2a). The
AR minigene was transiently transfected into AR-negative
MIA-PaCa-2 cells (Supplementary Fig. S1A), and both an
AR-FL (exon 3–exon 4) and an AR-V7 (exon 3–CE3) tran-
script were expressed, suggesting that canonical and alter-
native splicing occurs in the minigene-encoded AR transcript
(Fig. 2b). Of note, a natural preference for canonical splicing
was apparent as levels of the AR-FL transcript were almost
twofold higher than those of AR-V7 transcript. Minigene-
transfected MIA PaCa-2 cells were subsequently treated
with either AON-ISE or AON-ESE. Both splicing-directed
AONs displayed a significant reduction of AR-V7 transcript
expression but did not affect the expression levels of AR-FL
(Fig. 2b). Interestingly, the AON directed against the ESE
was less efficient in the knockdown of AR-V7 than the one
directed against the ISE. The specificity of both AONs was
assessed by transfecting control oligonucleotides containing
the AON sequence in the sense orientation. Neither of the
sense oligonucleotides, SON-ISE or SON-ESE, affected the
levels of either AR minigene-encoded transcript, whereas
expression levels were comparable to non-treated minigene-
expressing cells (Fig. 2b).
We further tested the AONs ability to knockdown AR-V7
in the CRPC-derived DuCaP and VCaP cell line models.
Both cell lines express AR-FL and AR-V7 at levels com-
parable to those from CRPC specimens (Supplementary
Fig. S1A,B). Upon addition of either AON, a strong
decrease in AR-V7 mRNA expression was noted in both cell
Chromosome X: 66905968 66914515       66915580                     66931244
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CAAUGUCUCUCUUUCAUACUAG
UGUCUC AG
GUCUCU
CUCUCU
UUUCAU
ACESCAN2 NetGene2 ESEFinder 
GACCCUGAAGAAAGGCUGA
CUGAAGA
AGAAAGG Predicted sites
AONs’ target sequences 
Fig. 1 Design of antisense oligonucleotides (AONs). Schematic
representation (not to scale) of the AONs designed to prevent splicing
of androgen receptor (AR) pre-mRNA into AR-V7 mRNA. AON-ISE
is complementary to the intronic splicing enhancer (ISE) sites pre-
dicted by ACESCAN2, and the cryptic “GA” splice acceptor dinu-
cleotide motif, predicted by NetGene2. AON-ESE is complementary
to the region harboring the ESEfinder-predicted exonic splicing
enhancer (ESE) sites. Predicted splicing enhancer sites are bold and
yellow, and the predicted cryptic splice acceptor site is on blue. The
corresponding genomic coordinates (Human Genome Assembly Feb-
ruary 2019, HG19) are marked by vertical lines pointing at the 5′ and/
or 3′ junctions of exon 3, cryptic exon 3 (CE3), and exon 4
Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7. . . 3697
lines (Fig. 2c). Western blot analysis of whole-cell extracts
using an AR-V7-specific antibody directed against CE3-
encoded amino acids showed a reduction of AR-V7 protein
levels upon treatment with the AONs (Fig. 2c). Treatment
with control SONs did not affect AR-V7 mRNA or protein
levels. AR-FL mRNA, as well as protein levels, remained
unchanged upon treatment with AONs (Fig. 2d). Because
CE3 lies in close proximity to other intronic regions that can
serve as cryptic exons to generate other AR variants, such as
AR-V1 or AR-V3, we assessed the expression levels of these
variants. AR-V1 mRNA levels were not affected in neither
cell line. However, AR-V3 expression was significantly
reduced in VCaP upon addition of AON-ISE, albeit to a
lesser extent than that of AR-V7 expression. Staining with
an AR N-terminus-specific antibody (N20) detected two
protein bands of about 75 kDa. The upper band had the
same size as the translated product in AR-V7-transfected
HeLa cells (data not shown), suggesting it corresponds to
endogenous AR-V7 protein levels (67 kDa). This band was
weakened after treatment with AON-ISE, similarly to band
detected with AR-V7-specific antibody. Interestingly, the
lower molecular size band (~66 kDa) was also reduced in
VCaP cells, presumably corresponding to AR-V3 (Fig. 2e).
Altogether, these results showed that AONs complementary
to the splice enhancer motifs in and around CE3 can effi-
ciently prevent AR-V7 mRNA synthesis in vitro.
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Fig. 2 Antisense oligonucleotide (AON)-mediated AR-V7 knock-
down. a Schematic diagram (not to scale) of the androgen receptor
(AR) minigene construct. Minimal regions containing AR exon 2,
cryptic exon 3 (CE3), exon 4 and their flanking regions are cloned into
a CMV-driven pEGFP-N3 expression vector. Vertical lines mark
positions of each AR gene fragment on chromosome X (Human
Genome Assembly February 2019, HG19). Primers for RT-qPCR are
marked with headed arrows. b AR-negative MIA PaCa-2 cells were
transfected with 500 ng AR minigene vector or with empty vector and
with 0.5 µM AONs (AON-intronic splicing enhancer (ISE) and AON-
exonic splicing enhancer (ESE)) or control sense oligos (SON-ISE and
SON-ESE). Relative expression of AR-FL and AR-V7 from the AR
minigene were measured by RT-qPCR analysis, four days after
transfection. Unpaired t-test; **p < 0.01; ***p < 0.001. AON-treated
vs non-treated cells; #p < 0.05 and ##p < 0.01. Bars represent the mean
± SD of three independent experiments. c–e Expression levels of AR-
V7, AR-FL, AR-V1, and AR-V3 in DuCaP and VCaP cells (determined
by RT-qPCR), 4 days after transfection with 0.2 µM AONs or control
oligos. Expression levels were compared with non-transfected cells
(NT). Below each graphs, western blot analysis of AR-V7 (anti-AR-
V7), AR-FL (N20), and truncated AR-Vs (N20) protein levels are
shown. Protein levels of β-actin (anti-β-actin) were used as protein
loading control. Unpaired t-test; *p < 0.05; **p < 0.01; ***p < 0.001.
Bars represent the mean ± SD of three independent experiments
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AON-mediated knockdown of AR-V7 results in
downregulation of AR-V7-target genes
AR-Vs have been described to have an overlapping but
distinct transcriptional output than AR-FL [6, 22]. Among
the genes described to be regulated by AR-Vs, specifically
by AR-V7, are the cell cycle regulatory genes UBE2C and
BUB1B [8, 11]. Microarray analysis of prostate (cancer)
specimens showed that, similarly to AR expression, UBE2C
and BUB1B are significantly upregulated in CRPC tissue
compared with benign tissues and androgen-sensitive pri-
mary prostate cancer and metastatic tissues (Fig. 3a). To be
able to discriminate between AR-FL and AR-V7 expression,
a qPCR validation was performed using CRPC samples
from an independent cohort. Both AR-FL and AR-V7
expression positively correlated with the expression of
UBE2C, but only AR-FL correlated with BUB1B expression
(Fig. 3b).
We next assessed the dependency of UBE2C and BUB1B
expression on AR-FL-mediated transactivation. Treatment
of VCaP cells with androgens induced expression of AR-
target gene KLK3 whereas treatment with enzalutamide, a
new-generation (full-length) AR antagonist, inhibited it
(Supplementary Fig. S2A). Androgen stimulation also
resulted in a marked induction of UBE2C and BUB1B,
which was reverted with the addition of enzalutamide (Fig.
3c). Forced expression of AR-V7 in VCaP cells resulted in a
significant upregulation of UBE2C and a weak, but obser-
vable increase of BUB1B expression (Fig. 3d). These last
results were obtained from cells grown in androgen-
depleted medium, and hence this expression profile was
considered a consequence of AR-V7 activity, exclusively.
From these results, it is clear that UBE2C is part of both
AR-FL and AR-V7 transcriptional program and, therefore,
it can be used to monitor the efficiency of AON-induced
AR-V7 knockdown.
Because AON-ISE resulted in a more efficient reduction of
AR-V7 expression levels in both DuCaP and VCaP cells than
AON-ESE, further experimentation did not include the latter
AON. Cells were transfected with various concentrations of
AON-ISE ranging from 0.02 µM to 0.5 µM. A significant AR-
V7 knockdown was achieved with doses above 0.02 µM, with
a clear dose-dependent decrease of AR-V7 mRNA levels in
both cell lines (Fig. 3e). The dose-dependent AON-ISE-
mediated knockdown of AR-V7 resulted in a dose-dependent
suppression of UBE2C. Although the maximum level of AR-
V7 splicing inhibition was achieved at 0.5 µM AON-ISE, a
dose of 0.35 µM suppressed UBE2C the most. Treatment with
AON-ISE at a dose of 0.2 µM and 0.35 µM doses resulted in a
significant downregulation of BUB1B in VCaP cells, but the
AON did not affect BUB1B expression in DuCaP cells
(Fig. 3f). AON-ISE treatment resulted in a specific AR-V7
knockdown and subsequently downregulation of the AR-V7-
target gene, UBE2C.
Intra-chromosomal translocation of the transmembrane
protease serine 2 (TMPRSS2) gene to the ETS family
member ERG is the most prevalent fusion in prostate cancer
[23] and the fusion gene is expressed in the VCaP cell line.
AR-V7, as well as AR-FL, have been described to mediate
transcriptional activation of TMPRSS2 [4, 12, 24]. Inter-
estingly, under castrated conditions, AON-ISE treatment of
VCaP cells resulted in downregulation of TMPRSS2-ERG
mRNA levels (Supplementary Fig. S2B), suggesting the
involvement of AR-V7 in the transcriptional regulation of
this fusion gene.
Effects of AON-ISE-mediated AR-V7 knockdown on
cell proliferation and apoptosis
Prostate cancer cells rely on androgens for proliferation and
survival, via activation of AR-FL and its targeted genes.
One of the functional consequences of AR-V7 protein
expression is its capacity to maintain proliferation of tumor
cells in the absence of androgens. Thus, we evaluated the
ability of AON-ISE to inhibit androgen-independent cell
proliferation. To eliminate any contribution of AR-FL, cells
were grown in androgen-depleted medium. A dose-
dependent effect on cell viability was observed in DuCaP
and VCaP upon treatment with AON-ISE but not with
control SONs (Fig. 4a). To exclude that the effect of AON-
ISE on cell viability is AR independent, we assessed the
effect of the AON on cell viability of AR-negative MIA
PaCa-2 cells. Treatment with three different concentrations
of AON-ISE had no effect on MIA PaCa-2 cell viability
(Fig. 4a). The reduction of cell viability was found to be a
Fig. 3 Effect of antisense oligonucleotide (AON)-intronic splicing
enhancer (ISE) on androgen receptor (AR)-V7-targeted gene expres-
sion. a Microarray analysis showing AR, UBE2C, and BUB1B gene
expression profiles in normal prostate (NP, n= 7), benign prostate
hyperplasia (BPH, n= 12), primary prostate cancer (PCa, n= 49),
castration-resistant prostate cancer (CRPC, n= 22), and metastasis (n
= 7). Microarray values (2 log scale are shown as the mean ± SD of
each group is depicted. Unpaired t-test; **p < 0.01; ***p < 0.001). b
Pearson correlation of AR-FL, AR-V7, UBE2C, and BUB1B mRNA
expression, obtained by RT-qPCR, in CRPC (n= 20) specimens.
Two-tailed p-values and Pearson r values are depicted. NS; p > 0.05. c
Relative UBE2C and BUB1B mRNA expression in VCaP cells,
determined 96 h after treatment with 0.1 nM R1881, or R1881 in
combination with 2 µM enzalutamide. Unpaired t-test; *p < 0.05; **p
< 0.01; ***p < 0.001. Bars represent the mean ± SD of three inde-
pendent experiments. d Relative mRNA expression levels of AR-V7,
UBE2C, and BUB1B in VCaP cells following transfection with an AR-
V7 expression vector. Unpaired t-test; *p < 0.05; ***p < 0.001). Bars
represent the mean ± SD of three independent experiments. e, f Rela-
tive mRNA expression from AR-V7 (e), UBE2C and BUB1B (f) in
DuCaP and VCaP cells, as determined 96 h after treatment with
increasing doses of AON-ISE, compared with non-transfected cells
(NT). Unpaired t-test; *p < 0.05; **p < 0.01; ***p < 0.001. Bars
represent the mean ± SD of three independent experiments
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result of the induction of apoptosis, which was marked by
an increase in Caspase-3/7 activity (Fig. 4b) and, conse-
quently, a cleavage of the Poly (ADP-ribose) polymerase 1
(PARP-1) protein [25, 26] (Fig. 4c).
A GapmeR AON was designed to bind complementary
to AR-V7 mRNA, inducing its degradation by RNAse H
(Supplementary Fig. S3 and Methods). GapmeR treatment
caused a reduction in cell viability of both DuCaP and
VCaP cells similarly to the AON-ISE treatment, without
affecting MIA PaCa-2 cell viability (Fig. 4d). This validated
the association of AR-V7 knockdown with the decrease in
cell viability.
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Reactivation of full-length AR signaling was expected to
revert the cell survival inhibitory effect of the AR-V7-
targeting AONs. Upon stimulation of DuCaP or VCaP cells
with the synthetic androgen R1881, AR-FL activity became
re-activated (Supplementary Fig. S2A) and cell viability
was not significantly affected by AON-ISE compared with
control SON-ISE-treated cells. Addition of enzalutamide to
the medium re-sensitized cells to AON-ISE treatment (Fig.
4e), demonstrating that AON-ISE is able to inhibit AR-V7-
mediated and androgen-independent induction of cell
proliferation.
Finally, to validate the effects of AON-ISE in a cell line
with a different genetic background, the CRPC-derived
22Rv1 cell line was used. 22Rv1 cells express AR-V7 at a
similar level than DuCaP and VCaP cells, and the ratio of
AR-V7-to-AR-FL mRNA levels in 22Rv1 cells was higher
than in these two cell lines, making it an ideal model to
study AR-V7 activity (Supplementary Fig. S1A,B). AON-
ISE treatment reduced cell viability of 22Rv1 cells by
induction of apoptosis at all doses tested (Supplementary
Fig. S4A,B). In addition, AR-V7 and UBE2C but not AR-FL
mRNA levels were significantly downregulated upon
treatment with AON-ISE (Supplementary Fig. S4C).
Effect of AON-ISE treatment over time
To assess whether the effect on cell viability matches the
downregulation of UBE2C, apoptosis and gene expression
were assessed in time following AON-ISE treatment. A
robust downregulation of AR-V7 was observed in both
DuCaP and VCaP cells at all time points up to 8 days after a
single administration of the AON. The highest knockdown
efficiency was observed between day 2 and day 4 hours
after transfection with a slow decrease in knockdown
thereafter. Consistently, expression levels of UBE2C fol-
lowed a similar trend (Fig. 5a).
Caspase-3/7 induction was observed from day 2 onwards
in both CRPC cell lines after treatment with AON-ISE (Fig.
5b). Cell cycle profiling of these cells showed an increase in
the sub-G1 cell population in AON-ISE-treated cells at day
3 after transfection (Fig. 5c). While the number of apoptotic
cells in VCaP remained stable over time, an increase was
noted in DuCaP cell cultures (Fig. 5c). Results in MIA
PaCa-2 cells showed no significant difference in the
induction of caspase activity or the number of (sub-G1)
apoptotic cells between AON and SON-treated cells (Sup-
plementary Fig. S5).
Discussion
Therapeutic drugs for advanced PCa are designed to block
androgen signaling, either by interfering with the androgen
synthesis or by blocking AR androgen binding. Androgen
deprivation therapy in patients with advanced or metasta-
sized disease gives a clear survival benefit of about
18 months, but ultimately tumor cells become resistant
leading to CRPC. While AR-targeting drugs efficiently target
the full-length receptor, they have no effect on C-terminally
truncated AR variants that increase upon CRPC develop-
ment. Several AR variants, such as AR-V7, act as con-
stitutively active transcription factors and promote androgen-
independent cell proliferation. Here, we have described a
proof of principle study where we employed AON technol-
ogy to prevent splicing of CE3 of AR-V7. These AONs
reduced AR-V7 mRNA and protein levels, without affecting
full-length AR mRNA and protein, and induced apoptosis of
CRPC cells in a low androgen environment.
The publically available computer-based algorithms
ACESCAN2 and ESEFinder were used to predict potential
splicing enhancers within CE3 and its flanking regions. An
ISE and an ESE site in and around CE3 of the AR pre-
mRNA have been reported. Mutations in these motifs
impaired binding of splicing factors U2AF65 and ASF/SF2
and prevented the generation of an AR-V7 transcript [12]. In
our results, several ISE and ESE sites were predicted in and
around CE3, and all (partially) overlapped with the ISE and
ESE motifs described before [12]. This suggests that not a
single ISE or ESE site may be pinpointed as most relevant
for AR-V7 mRNA splicing, and hence, AON-ISE and AON-
ESE were designed to encompass all predicted ISE and ESE
motifs, respectively. Comparing both AONs used in this
study, AON-ESE affected the generation of AR-V7 tran-
scripts at a much lesser extent than AON-ISE. The AON-
ISE sequence is directed not only against the predicted ISE
motifs but also against the cryptic SA site. The fact that SA
Fig. 4 Effect of antisense oligonucleotide (AON)-intronic splicing
enhancer (ISE) in cell viability and apoptosis. a Dose-dependent effect
of AON-ISE-mediated androgen receptor (AR)-V7 knockdown on cell
viability of DuCaP and VCaP cells compared with SON-treated cells.
AR-negative MIA PaCa-2 cells were used as a negative control.
Unpaired t-test; *p < 0.05; **p < 0.01; ***p < 0.001. Bars represent the
mean ± SD of three independent experiments. b Induction of apopto-
sis, as determined by Caspase-3/7 induction, in DuCaP and VCaP cells
after treatment with different doses of AON-ISE. AR-negative MIA
PaCa-2 cells were used as a negative control. Bars represent the mean
± SD of three independent experiments. cWestern blot analysis of full-
length and cleaved PARP-1 protein (anti-PARP) in DuCaP and VCaP
cells, 96 h after transfection with 0.2 µM AON-ISE or sense oligonu-
cleotides. Protein levels of β-actin (anti-β-actin) was used as loading
control. d Relative cell viability of DuCaP, VCaP, and MIA PaCa-2
cells after treatment with increasing doses of GapmeR-AR-V7, com-
pared with GapmeR-Control-treated cells. Unpaired t-test; *p < 0.05;
**p < 0.01. Bars represent the mean ± SD of three independent
experiments. e Relative cell viability of AON-ISE or SON-ISE-
transfected (0.2 µM) DuCaP and VCaP cells grown in medium con-
taining 0.1 nM R1881, or R1881 in combination with 2 µM enzalu-
tamide. Unpaired t-test; *p < 0.05; **p < 0.01; ***p < 0.001. Bars
represent the mean ± SD of three independent experiments
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sites are essential for splicing, and enhancers only stimulate
the splicing process, may explain why AON-ISE is more
effective in blocking AR-V7 splicing than AON-ESE.
Furthermore, in the context of the AR transcript, the ISE
enhancer may have superior activity over the ESE enhancer,
as has been suggested by Liu et al. [12].
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The use of a minigene was key to confirm the dis-
turbance in splicing and to validate the importance of the
predicted ISE and ESE sites. Upon transfection, both AR-FL
and AR-V7 transcripts were expressed from the minigene
construct. Interestingly, relative expression of the AR-V7
transcript from the minigene was lower than that of AR-FL.
Although this might suggest an intrinsic preference of
splicing factors for binding to canonical splicing signals,
this effect could as well be linked to the particular pool of
splicing factors present in the AR-negative MIA PaCa-2 cell
line and therefore expression levels of the two mini tran-
scripts could differ among cell line models.
Both of our AONs were generated with a phosphor-
othioate backbone and a 2′-O-methyl group modification at
the sugar chain, chemical modifications that make them
resistant to RNAse activity. This could allow our AONs to
remain stable throughout turnover of pre-existing AR-V7
proteins achieving a maximum effect. The physiological
effect of AON-ISE occurred between day 3 and day 4,
likely the time required for degradation of AR-V7 protein to
a threshold that rendered cells sensitive to the oligo
treatment.
Curiously, AON-ISE treatment in VCaP cells resulted in
the downregulation of another AR mRNA variant, AR-V3.
The intronic region where CE3 and the predicted ISE sites
lie, also harbors the cryptic exon that is present in the AR-V3
splice variant [4, 27]. AON-ISE binding to its target
sequence could disturb recruitment of splicing factors to one
or more unknown splicing signals critical for the synthesis
of AR-V3 mRNA. Although AR-V3 is one of the most
abundant variants, AR-V3 is considered inactive due to its
permanent cytoplasmic localization, and therefore func-
tional consequences of AR-V3 knockdown are unlikely.
AON treatment demonstrated efficacy in three CRPC cell
line models, but the response of each cell line to the treat-
ment was not identical. At the mRNA and protein level, the
effect of AON treatment seemed to be less pronounced in
DuCaP than in VCaP cells. This probably reflects the dif-
ference in AR transcript levels between these two cell lines.
AR-FL, as well as AR-V7 mRNA expression, is markedly
higher in DuCaP than in VCaP, resulting from a higher AR
copy number (Supplementary Fig. S1C). This also could
explain why the effect of AON-ISE on AR-V3 mRNA levels
was only visible in VCaP cells, but not in DuCaP. Con-
tradictory to the knockdown efficiency, the effect of AON-
ISE in cell viability of DuCaP was a lot more striking than
in VCaP cells. DuCaP cells showed a stronger dose-
dependent sensitivity to AON-ISE treatment with a higher
cleaved-to-full-length PARP-1 ratio and a consistent higher
amount of apoptotic cells than the counterpart cell line.
These observations indicated that the physiological depen-
dency on AR-V7 for cell survival or proliferation, but not
the knockdown efficiency per se dictates the sensitivity to
AON-ISE treatment.
It has been shown recently that degradation products of
AONs can affect cell proliferation and differentiation [28].
Sense oligonucleotides (SONs) having identical backbone
modifications as the AONs were used in our experiments as
negative controls. None of the SONs affected cell viability
of the transfected cells, even at the highest dose tested
(0.5 µM), highlighting the specificity of our system. Fur-
thermore, treatment with AON-ISE in the AR-negative MIA
PaCa-2 showed no signs of AON-mediated toxicity at all
concentrations tested.
Androgen stimulation has been reported to reduce AR
mRNA levels by repressing AR transcription, a process that
can be reverted upon treatment with AR inhibitors or fol-
lowing androgen withdrawal [29, 30]. In VCaP cells, this
negative feedback was evident by a reduction in the
expression levels of AR-FL and AR-V7 mRNA upon treat-
ment with R1881. Transcripts levels were restored after
addition of enzalutamide to the culturing medium. Here,
androgen stimulation, as well as overexpression of AR-V7,
resulted in a significant induction of UBE2C whereas
enzalutamide treatment or AON-ISE-mediated knockdown
of AR-V7 promoted its downregulation, validating it as both
an AR-FL- and an AR-V7-target gene.
Another gene reported to be regulated by both AR-FL
and AR-V7 is TMPRSS2 [4, 12, 24]. Fusion of the
TMPRSS2 and ERG genes is the most prevalent gene fusion
in prostate cancer, occurring in about 50% the cases [23].
Knockdown of TMPRSS2-ERG has been reported to inhibit
cell proliferation in vitro [31], and knockdown of ERG
reduced tumor progression in vivo in an orthotopic mouse
model [32]. AON-ISE-mediated AR-V7 knockdown resul-
ted in downregulation of TMPRSS2-ERG mRNA levels in
VCaP cells, arguing for a role of AR-V7 in the maintenance
of cell viability via TMPRSS2-ERG activation. The effect of
AON-ISE in cell viability, however, was also observed in
22Rv1 cells (TMPRSS2-ERG fusion gene negative). Thus,
AR-V7-mediated cell viability cannot be solely attributed to
the regulation of TMPRSS2-ERG.
Fig. 5 Time follow-up of antisense oligonucleotide (AON)-intronic
splicing enhancer's (ISE’s) effect. a Expression levels of AR-V7 and
UBE2C in DuCaP and VCaP cells, determined at different time points
after treatment with 0.2 µM of AON-ISE, normalized to values from
un-transfected cells. Unpaired t-test; *p < 0.05; **p < 0.01; ***p <
0.001. Bars represent the mean ± SD of three independent experiments.
b Relative Caspase-3/7 activity measured at different time points in
DuCaP and VCaP cells treated with 0.2 µM of AON-ISE or SON-ISE.
Unpaired t-test; **p < 0.01; ***p < 0.001. Bars represent the mean ±
SD of three independent experiments. c Increase in DuCaP and VCaP
sub-G1 cell population at day 3 and day 4, following knockdown of
AR-V7 by AON-ISE, as analyzed by propidium iodide staining and
flow cytometry. Graphs show gated percentages of cells corresponding
to sub-G1 (sky blue), G1 (red), S (blue), and G2/M (yellow) cell cycle
phases
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Previous studies have shown that UBE2C knockdown
downregulates cell proliferation and activates the cellular
apoptosis pathway [33]. AR-V7 has been reported to med-
iate UBE2C transcriptional activation by direct occupancy of
its promoter [24]. Interestingly, AON-ISE-mediated knock-
down of AR-V7 and the subsequent downregulation of
UBE2C were accompanied by an increase in Caspase-3/7
activity and an inhibition of androgen-independent cell
proliferation. This suggests a role for UBE2C as a key
regulator of AR-V7-promoted cell viability.
Sustained cell proliferation in CRPC cells under castrate
levels of androgens clearly demands for the development of
new AR-targeted therapies. AONs have been shown to
mediate significant biological effects in vitro and in vivo,
reverting diverse disease phenotypes [34–37]. AON tech-
nology is nearing clinical relevance as it offers novel ther-
apeutic opportunities for severe, untreatable or chronic
diseases, including cancer [38–43]. Here, we present the
first report on the use of a splice-switching AON technology
in CRPC. Our results showed an AON-mediated specific
and efficient knockdown of AR-V7, which induces cell
death in three CRPC-derived cell line models. These results
certainly are promising and warrant further in vivo
investigation.
Targeting of internal organs like the prostate or dis-
seminated prostate cancer cells, typical for CRPC, would
require systemic administration of AONs. Systemic
administration of splice-switching AONs has demonstrated
significant clinical benefits before. AON treatment corrected
the open reading frame of the dystrophin DMD mRNA and
ameliorated symptoms in Duchenne muscular dystrophy
patients [44, 45]. Pharmacokinetic and pharmacodynamic
profiling of our AONs is pivotal for further optimization of
our AON as a drug system [46, 47]. The AON chemistry
design and the choice of delivery method will ultimately
determine its targeting efficacy.
Materials and methods
Splicing signals prediction
A 4-kb sequence containing an AR intronic region known as
CE3 and its flanking sequences (516-bp upstream and 2418-
bp downstream of CE3) was screened for the presence of
intronic and exonic splice enhancer motifs. The publically
available computer-based algorithms ACESCAN2 (http://
genes.mit.edu/ acescan2/index.html) and ESEFinder (http://
rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi) were used
to predict potential ISEs and ESEs, respectively. The cryptic
splicing acceptor site was detected by screening the same
sequence with the NetGene2 server (http://www.cbs.dtu.dk/
services/NetGene2/).
Design of AONs
Two RNA AONs, a 22 nucleotides long AON-ISE and a
19 nucleotides long AON-ESE, together with two control
sense RNA oligonucleotides SON-ISE and SON-ESE
were synthesized and modified with a phosphorothioate
backbone and 2′-O-methyl groups at the sugar chain
(Eurogentec, The Netherlands). Oligos were dissolved in
nuclease-free water. A 20 nucleotides long GapmeR
AONs, GapmeR-AR-V7, was designed using SFold
software [48] (http://sfold.wadsworth.org/cgi-bin/index.
pl). The chimeric GapmeR (RNA5-DNA10-RNA5) was
chemically modified and synthesized as described above
for the RNA AONs. The GapmeR sequence described by
Wheeler et al. [49] was used as a control. Analytical ion
exchange high-pressure liquid chromatography (HPLC)
and matrix-assisted laser desorption/ionization time-of-
flight mass spectrometer (MALDI-TOF MS) were chosen
to assess the purity of all oligonucleotides, and a purity of
>90% was considered as pure. AON sequences are listed
in Supplementary Table S1.
Cell culture
The CRPC-derived 22Rv1 (ATCC# CRL-2505), DuCaP,
and VCaP (kindly provided by dr. Kenneth J. Pienta, Johns
Hopkins, Baltimore, USA), the prostate cancer-derived
LNCaP (ATCC# CRL-1740), PC-3 (ATCC# CRL-1435),
and the bladder carcinoma-derived 5637 (ATCC# HTB-9)
cell lines were maintained as monolayer cultures in Roswell
Park Memorial Institute (RPMI)-1640 medium (Invitrogen),
supplemented with 2 mM L-glutamine and 10% fetal calf
serum (FCS; Sigma). Pancreatic carcinoma MIA-PaCa-2
cells (ATCC# CRL-1420) were grown in Dulbecco’s
modified Eagle's medium (DMEM) (Invitrogen) with
4.5 g/ml glucose and 1 mM pyruvate, supplemented with 2
mM L-glutamine and 10% FCS and 2.5% of horse serum
(Invitrogen). For hormone stimulation experiments, 0.1 nM
of synthetic androgen R1881 (PerkinElmer) was added to
the medium in combination with 2 µM enzalutamide (Sell-
eck Chemicals) or 0.2% dimethyl sulfoxide (as a vehicle
control). Results were reproduced in at least three inde-
pendent experiments. All cultures were maintained in a
humidified atmosphere at 37 °C and 5% CO2. Cell lines
were authenticated in 2016 using the PowerPlex 21 system
(Promega) by Eurofins Genomics (Germany). Cells were
frequently tested for Mycoplasma infection, using a Myco-
plasma-specific PCR, and propagated for no >6 months or
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30 passages after resuscitation from the authenticated
stocks.
Construction of minigene and AR-V7 expression
vector
The AR minigene was built according to sequence coordi-
nates described by Liu et al. [12]. Briefly, three PCR
amplicons were generated using Phusion High-Fidelity
DNA Polymerase (New England Biolabs) and joined
together by SOEing PCR. Genomic DNA from the (normal)
human genomic DNA was used as the template to amplify
AR exon 3, CE3, exon 4, and their flanking regions. Exon 4
was amplified including a downstream 447-base-pair
flanking region. CE3 was amplified including 364-bp
upstream and 1067-bp downstream flanking regions and
AR exon 4 amplicon included 469 bp from the upstream
flanking region. For SOEing PCR, all three fragments
contain 20-bp overlapping sequences incorporated as
overhangs in the forward and reverse primers. The assem-
bled minigene was directionally cloned into the pEGFP-N3
vector (Clontech) between the BglII and NotI sites (thereby
removing the eGFP region). For cloning of the eukaryotic
expression vector pCMV-AR-V7, CE3 was amplified from
human genomic DNA. The fusion between an exon 3 and
CE3 was achieved by SOEing PCR using Phusion High-
Fidelity DNA Polymerase (New England Biolabs). The
forward primers for the sewed amplicons were com-
plemented with a 5′-GAGATG-3′ overhang and a HindIII
site, and the reverse primers with a 5′-GTTGTT-3′ fol-
lowing an MfeI restriction site. The insert was directionally
cloned into the pEGFP-N3-derived CMV-driven expression
vector backbone vector. Correct cloning was verified by
Sanger DNA sequence analysis of PCR products, purified
using Wizard PCR preps DNA purification system (Pro-
mega). Primer sequences for cloning and sequencing ana-
lysis are listed in Supplementary Table S2.
Transfection with AONs
One day before transfection, 140,000 cells (DuCaP/VCaP)
or 70,000 cells (22Rv1/MIA-PaCa-2) were seeded per well
of a 24-well plate, in a total volume of 500 µl medium. After
trypsinization, cells were collected and seeded in charcoal-
stripped serum-containing medium to wash away traces of
androgens previously reported to be present in FCS [50].
Transfection mixtures were prepared by combining oligo-
nucleotides (AON/SON or GapmeRs) in a desired con-
centration with X-tremeGENE™ 9 transfection reagent
(Roche), both dissolved in Opti-MEM I Reduced serum-
free medium (Invitrogen). A mix of transfection reagent
alone, i.e., without oligonucleotide, was used as non-
transfected control. Mixes were incubated at room
temperature for 15 min before addition to the cells in a
dropwise manner. For overexpression studies, 140,000
VCaP cells were seeded per well in 24-well plates. Twenty-
four hours later, cells were transfected with 250 ng of
pCMV-AR-V7 expression vector or empty vector control.
For minigene experiments, 70,000 MIA-PaCa-2 cells were
seeded per well in 24-well plates and after 24 h, cells were
co-transfected with 500 ng of minigene or empty vector and
0.5 µM of the desired oligonucleotide. All experiments were
performed at least three times.
RNA isolation and reverse transcription-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen)
according to manufacturer’s protocol. Concentration and
purity of the RNA was determined on a Nanodrop-1000
spectrophotometer (Thermo Scientific). Subsequently, 2 μg
of total RNA was treated with DNaseI and used to syn-
thesize complementary DNA using random hexamer pri-
mers and SuperScript II Reverse Transcriptase (Invitrogen).
Real-time PCR (qPCR) analysis was performed using
LightCycler 480 SYBR Green I Master Mix (Roche) and
gene-specific primers (Supplementary Table S3). Crossing-
point (Cp) values were determined using the LightCycler
480 SW 1.5 software (Roche). RNA not subjected to
reverse transcriptase was used as a control for non-specific
PCR amplification. Expression levels of the human het-
erochromatin protein 1 binding protein 3 (HP1BP3), the
hypoxanthine phosphoribosyltransferase 1 (HPRT1) and the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
genes were used for normalization and relative gene
expression levels were calculated according to the mathe-
matical model for relative quantification in real-time PCR
[51]. To determine TMPRSS2-ERG fusion transcript levels,
a forward primer directed to exon 1 of the TMPRSS2
transcript together with a reverse primer directed to exon 4
of the ERG transcript were used [52].
Western blot analysis
One day before transfection, 1,200,000 (DuCaP/VCaP)
cells were seeded in 10-cm dishes. When cells reached 70%
confluency, oligonucleotide transfection was performed.
Four days after transfection, cells were harvested and
washed. Cell pellets were lysed using Laemmli lysis buffer
(1 mM CaCl2, 2% sodium dodecyl sulfate (SDS), 60 mM
Tris-Glycine pH 6.8) supplemented with 1:50 β-mercap-
toethanol (Merck). Lysates were homogenized by sheering
them through a 0.5 × 25 mm syringe needle. Protein con-
centration was measured using the Odyssey CLx Imaging
System (LI-COR) and Image Studio software (LI-COR),
after staining with Coomassie brilliant blue (Merck) with
serial dilutions of bovine serum albumin as a standard. A
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total of 100 µg of protein was subjected to SDS-
polyacrylamide gel electrophoresis using 7.5% poly-
acrylamide gels. Proteins were electrotransferred onto
polyvinylidene fluoride membranes (Hybond 0.45 µm,
Amersham Biosciences). Membranes were blocked for 1 h
in phosphate-buffered saline with Tween-20 (PBS-T)/5%
non-fat dry milk and incubated overnight with the primary
antibody. The mouse monoclonal-antibody anti-AR-V7
(Precision Antibody, #AG10008), the rabbit polyclonal
AR antibody N20 (Santa Cruz, SC-816), the rabbit
monoclonal-antibody anti-PARP (Cell Signaling, #46D11),
and the mouse monoclonal-antibody anti-β-actin (Sigma-
Aldrich, clone AC-15) were used, diluted 1:500, 1:50,000,
1:1000, and 1:5000 in PBS-T/5% non-fat dry milk,
respectively. The Horseradish peroxidase-conjugated
donkey-anti-rabbit antibody (Amersham Biosciences,
N4934) or sheep-anti-mouse antibody (Amersham Bios-
ciences, NXA931) diluted 1:50,000 in PBS-T were used as
secondary antibodies. Protein bands were detected using
ECL and Hyperfilm (Amersham Biosciences). Results were
reproduced in two independent experiments.
Tissue collection and processing
CRPC tissue (n= 20) was obtained by transurethral resec-
tion of prostate tumor tissue (TURP). TURP specimens
were snap frozen in liquid nitrogen. Regions of CRPC
tumors (n= 20) with high percentage of epithelial tumor
cells (>50%) were selected for cryo-sectioning. The use of
patient materials was approved by the local ethics com-
mittee of the Radboud university medical center (CMO
Arnhem-Nijmegen).
Microarray analysis
Microarray gene expression analysis on normal prostate,
prostate cancer, and CRPC tissue samples were performed
and described previously by Leyten et al. [53].
Cell viability assay
To assess cell viability, 10,000 (22Rv1), 20,000 cells
(DuCaP/VCaP), or 500 cells (MIA-PaCa-2) were cultured
in 96-well culture plates. Transfection with oligonucleotides
was done 24 h after seeding. Four days after transfection,
cell viability was measured using 3-(4,5-dimethylthiazol-2-
yl)−2,5-dephenyltetrazolium bromide (MTT, 1 mg/ml)
assays. Alternatively, cell viability was measured using
CellTiter-Glo luminescence assays (Promega), following
the manufacturer’s instructions. Absorbance (at 490 nm)
and luminescence were measured using a Victor3 multilabel
reader (PerkinElmer). Medium only was used as back-
ground control. To calculate the relative cell viability, cell
viability values for each condition were normalized to the
average of the cell viability values for control oligo-
transfected cells. Each experiment was performed in tripli-
cate and repeated at least three times.
Apoptosis assay
In parallel to the cell viability assays, cells were seeded into
96-well plates for assessment of Caspase-3/7 activity using
the Apo-ONE Homogenous Caspase-3/7 Assay (Promega),
following manufacturer’s instructions. After 4 h of incuba-
tion, luminescence was measured on a Victor3 multilabel
reader (PerkinElmer). The luminescence signal from med-
ium alone was used as background. Caspase-3/7 activity
was normalized to values in control oligo-transfected cells.
Each experiment was performed in triplicate and repeated at
least three times.
Cell cycle analysis
One day before transfection, 280,000 cells (DuCaP/VCaP)
were seeded per well of a 12-well plate. The next day, cells
were transfected with oligonucleotides as described above.
Samples were harvested at different time points after
transfection. Briefly, cells were harvested and washed with
0.9% NaCl. Cell pellets were resuspended in Hank's
balanced salt solution (Invitrogen) and cells were fixed with
ice-cold ethanol (58%). Fixated cells were centrifuged,
resuspended in PBS, and treated with RNase A (100 µg/ml,
Sigma) for 40 min at 37 °C. Subsequently, cells were
stained with propidium iodide (40 µg/ml, Sigma) for 15 min
in the dark. The samples were analyzed on a FC500 Flow
Cytometer (Beckman-Coulter) and histograms were created
and analyzed using Kaluza® Flow Analysis software
(Beckman-Coulter). Results were reproduced in two inde-
pendent experiments.
Statistical analysis
The data are presented as means ± SD from at least three
independent experiments. Two-tailed paired and unpaired t-
tests were performed using GraphPad Prism (GraphPad
Software, Inc.). Pearson correlation coefficients were used to
determine the relationships between relative gene expression
profiles, considering a 95% confidence interval. A p-value of
< 0.05 was considered statistically significant and p < 0.05 is
represented by one star (*), p < 0.01 is represented by two
stars (**), and p < 0.001 is represented by three stars (***).
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